Comparative Pharmacology
Head-to-head clinical analysis: SEYSARA versus TETRACYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEYSARA versus TETRACYCLINE HYDROCHLORIDE.
SEYSARA vs TETRACYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sarecycline is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also has anti-inflammatory properties through inhibition of neutrophil chemotaxis and reduction of pro-inflammatory cytokines.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
100 mg orally once daily with food.
250-500 mg orally every 6 hours; or 500 mg to 1 g intravenously every 12 hours. Maximum oral dose: 4 g/day.
None Documented
None Documented
The terminal elimination half-life after oral administration is approximately 12 hours (range 10-14 hours), supporting once-daily dosing.
6-11 hours (prolonged to 57-120 hours in severe renal impairment; reduced in hepatic dysfunction; clinically relevant for dosing interval adjustments).
Renal excretion of unchanged drug accounts for approximately 66% of the administered dose; fecal elimination is about 33%.
Renal (60% unchanged via glomerular filtration), biliary (40% as active drug and metabolites, with enterohepatic recirculation; fecal elimination of unabsorbed drug).
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic